The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Stomach Neoplasms Clinical Trial

Official title:

PD-1 Inhibitor Plus Chemotherapy as Conversion Therapy in Unresectable Gastric Cancer (STARS-GC01): A Single-arm, Single-center, Prospective Clinical Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04694183
• Other study ID #: STARS-GC01
• Status: Completed
• Phase: Phase 2
• Start date: August 17, 2020
• Est. completion date: May 6, 2023

Study information

• Verified date: February 2024
• Source: The First Hospital of Jilin University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis rate.Studies have shown that patients with good pathological response after preoperative neoadjuvant therapy (such as tumor regression grade, TRG0 or 1) have a better prognosis.The purpose of this study is to treat patients with advanced gastric cancer who are difficult to perform R0 surgery with chemotherapy combined with immunotherapy. At the same time as the primary cancerous lesions are reduced, the distant metastatic lesions are effectively controlled in order to perform R0 surgery and to improve the survival rate of patients with advanced gastric cancer.

Description:

The interventions include camrelizumab and chemotherapy selected based on the use of different metastatic sites as conversion therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: May 6, 2023
• Est. primary completion date: May 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The patient voluntarily participates in the study with full informed consent and signs a written informed consent form.

2. Age 18-75 years old, male or female.

3. HER-2 negative unresectable gastric cancer.

4. Patients with gastric cancer who PD-L1+(CPS=1)or MSI-H/dMMR, or EBV(+).

5. Patients were assessed by physicians before enrollment to determine eligibility for conversion therapy.

6. The expected survival time of the patient is= 12 weeks.

7. ECOG 0-1.

8. The patient has good organ function: no blood transfusion or colony-stimulating factor and thrombopoietin have been received in the 14 days before the first study, neutrophil count =1.5×109/L, platelet count =80×109/ L hemoglobin = 80 g/L, serum creatinine = 1.5 times the upper limit of normal (ULN), total bilirubin = 1.5 times the upper limit of normal (ULN), ALT, AST = 2.5 times ULN (without liver metastasis) or = 5 times ULN (such as liver metastasis occurred), albumin =30 g/L. Requirements for coagulation function: International normalized ratio (INR) = 1.5 times ULN, prothrombin time (PT) = 1.5 times ULN, activated partial thromboplastin time (aPTT) = 1.5 times ULN. Requirements for electrolytes: the corrected serum calcium, blood potassium, and blood magnesium are within the normal range;

9. Women of childbearing age are required to have a pregnancy test (serum or urine) within 7 days of entry and the results are negative and are willing to use appropriate methods of contraception during the trial and 8 weeks after the last drug is given. For men, it should be surgical sterilization or consent to the use of appropriate methods of contraception during the trial and 8 weeks after the last administration of the experimental drug.

Exclusion Criteria:

1. Those who are known to be allergic to the study drug or any of its excipients or have had severe allergic reactions.

2. Patients who have received chemotherapy and monoclonal antibodies within 21 days and those who have received radiotherapy within 14 days.

3. Participated in other clinical trials within 21 days before screening.

4. Other malignant tumors have been diagnosed within 5 years before entering the study, except for skin basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, or intraductal carcinoma in situ of the breast that can be treated locally and cured.

5. There is uncontrollable or symptomatic active central nervous system (CNS) metastasis, which can be manifested as clinical symptoms, cerebral edema, spinal cord compression, cancerous meningitis, leptomeningeal disease and/or progressive growth; imaging Prompt asymptomatic spinal cord compression, except for those who have been evaluated by specialists as stable and do not need treatment for the time being; For those who have received CNS metastasis treatment, imaging examinations during the screening period have shown that they have been stable for =4 weeks and have been stopped before the first study administration Except for systemic hormone therapy (prednisone or other curative hormones with a dose> 10 mg/day) for = 4 weeks.

6. Poorly controlled pleural effusion, abdominal effusion, or pericardial effusion.

7. Poorly controlled tumor-related pain; patients who need analgesic treatment, must receive a stable dose of treatment before participating in the study; should be suitable for palliative radiotherapy (for example, bone metastasis or metastasis that causes nerve damage) before enrollment. If appropriate, consider local treatment of asymptomatic metastatic lesions whose further growth may cause functional defects or intractable pain (for example, epidural metastases not related to spinal cord compression).

8. Peripheral neuropathy or hearing loss = 2 (according to NCI-CTCAE 5.0).

9. Pregnant or (confirmed by blood or urine HCG test) or breastfeeding women or subjects of childbearing age are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until after the last trial treatment at least 6 months.

10. Patients with moderate to severe liver and kidney dysfunction.

11. Diabetes that is difficult to control (refers to the large fluctuations in blood glucose under standard insulin treatment and frequent blood glucose monitoring, which affects the life of the patient and frequent hypotension).

Related Conditions & MeSH terms

• Stomach Neoplasms

Intervention

Drug:
• Camrelizumab
200mg, intravenous drip administration, d1, every 3 weeks.
• S-1
Oral, d1-14, every 3 weeks.
• Oxaliplatin
130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
• Paclitaxel
Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).

Locations

Country	Name	City	State
China	First Hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Quan Wang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	R0 resection rate	Defined as no residue under the microscope after resection	Within 1 month of surgery.
Secondary	Pathologic complete response	The number of people who have achieved complete pathological remission accounted for the proportion of people who met the plan.	Within 1 month of surgery.
Secondary	Overall survival	The time from the start of system therapy to the death of any cause.	From the start of system therapy to death from any cause.
Secondary	2-year survival rate	Percentage of subjects who are alive without death event at two years.	2 years from the start of system therapy.
Secondary	Adverse events(all grades)	Assessed per Common Terminology Criteria for Adverse Events(CTCAE) version 5.0	From the start of system therapy to 6 months after surgery.
Secondary	Serious adverse events(=grade 3)	Assessed per Common Terminology Criteria for Adverse Events(CTCAE) version 5.0	From the start of system therapy to 6 months after surgery.